Delcath Sys Stock Price, News & Analysis

Delcath Systems (DCTH) will host an Investor Update on December 2, 2021, from 10 AM to 1 PM ET, focusing on its Hepzato Kit and its applications in treating liver cancers. Physicians will present updated data from the Focus trial and discuss the potential of Hepzato in treating hepatic-dominant metastatic ocular melanoma, colorectal cancer, and intrahepatic cholangiocarcinoma. The event will be accessible via a live webcast, with the archive available afterward on the company's website.

Delcath Systems (DCTH) announced a conference call on November 9, 2021, at 8:30 AM ET to discuss its Q3 2021 results ending September 30, 2021. The company specializes in interventional oncology, focusing on liver cancers through its proprietary percutaneous hepatic perfusion (PHP) system. In the U.S., it markets the system as HEPZATO KIT, while in Europe, it operates as CHEMOSAT Hepatic Delivery System. Interested parties can join the call via toll-free or international numbers, or stream it online.

Delcath Systems, Inc. (DCTH), a leader in interventional oncology, will present at three key healthcare conferences in September 2021. The H.C. Wainwright 23rd Annual Global Investment Conference runs from September 13-15, featuring on-demand presentations starting September 13 at 7:00 AM (ET). Next is the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 20-23, with a presentation on September 21 at 12:25 PM (ET). Lastly, the Cantor Fitzgerald Healthcare Conference will occur September 27-30, with a presentation on September 29 at 4:40 PM (ET).

Delcath Systems, Inc. (DCTH) reported its Q2 2021 financial results, showing product revenue of approximately $536K, up from $379K year-over-year. Despite this growth, the company incurred a net loss of $6.4M compared to a net income of $4.3M in Q2 2020. Key highlights include positive results from the FOCUS Phase III trial of HEPZATO™ KIT, with a 29.2% overall response rate in treated patients. Additionally, Delcath's CHEMOSAT® received updated guidance from the UK's National Institute for Health and Care Excellence, enhancing treatment funding prospects.

Delcath Systems (DCTH) has secured a debt facility of up to $20 million from Avenue Venture Fund, with an initial $15 million funded at closing. This financing aims to support the upcoming NDA filing for HEPZATO™, targeting the treatment of hepatic-dominant metastatic ocular melanoma, anticipated in early 2022. CEO Gerard Michel expressed optimism regarding the partnership, which will aid in advancing Delcath's innovative cancer treatment approaches.

Delcath Systems, Inc. (Nasdaq: DCTH) announced its participation in two key conferences. The BTIG Virtual Biotechnology Conference is set for August 9, 2021, from 10:00-10:25 AM ET, featuring management-led 1x1 investor meetings. The Canaccord Genuity 41st Annual Growth Conference will follow on August 11, 2021, at 10:00 AM ET, with a webcast available at this link. Delcath specializes in treating liver cancers through its proprietary PHP system.

Delcath Systems, Inc. (Nasdaq: DCTH) will host a conference call on August 10, 2021, at 8:30 AM ET to discuss its second-quarter results for the period ending June 30, 2021. The call will be accessible via phone and online. Delcath focuses on providing innovative treatments for rare liver cancers through its proprietary PHP system, which allows high-dose chemotherapy directly to the liver, minimizing systemic side effects. In Europe, the PHP system is marketed as CHEMOSAT, while in the U.S., it is under the name HEPZATO KIT.

Delcath Systems, focused on interventional oncology for liver cancers, will present at the Access to Giving Virtual Conference on July 13, 2021, at 3 p.m. ET. CEO Gerard Michel will lead the discussion. This conference allows companies to engage with investors while supporting charitable causes. Registration is free and can be done online. Delcath’s investigational product, HEPZATO KIT, aims to deliver high-dose chemotherapy to the liver, although it is not approved by the FDA in the U.S. The system is marketed in Europe as Delcath CHEMOSAT.

Delcath Systems is set to join the Russell Microcap® Index on June 28, 2021, following the annual reconstitution. This membership will remain for one year and includes automatic inclusion in growth and value style indexes. The CEO, Gerard Michel, emphasized that this milestone enhances the company's visibility among investors. Russell indexes manage approximately $10.6 trillion in assets, being widely used by institutional investors for benchmarking. Delcath focuses on treating liver cancers using its proprietary PHP system, marketed as HEPZATO in the US and CHEMOSAT in Europe.